UC-MSCs
UC-MSCs is a pharmaceutical drug with 23 clinical trials. Currently 4 active trials ongoing. Historical success rate of 75.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
7
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
42.9%
3 of 7 finished
57.1%
4 ended early
4
trials recruiting
23
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.
Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial
UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
Clinical Trials (23)
Phase II Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance.
Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial
UCMSCs Combined With Standard Therapy for the Treatment of Newly Diagnosed Type 1 Diabetes
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2)
Phase I Clinical Trial of UC-MSCs in the Treatment of Knee Osteoarthritis
Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19
Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.
Study of Human Umbilical Cord Mesenchymal Stem Cell in Patients With Cirrhosis Due to Hepatitis B (Compensation Stage)
Umbilical Cord Tissue (UC) Derived Mesenchymal Stem Cells (MSCs) Versus Placebo to Treat Acute Pulmonary Inflammation Due to COVID-19
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis
Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy
Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19)
Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia
Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Severe COVID-19
Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia
Therapy for Pneumonia Patients iInfected by 2019 Novel Coronavirus
The Safety and Effects of Mesenchymal Stem Cell (MSCs) in the Treatment of Rheumatoid Arthritis
Safety and Exploratory Efficacy Study of UCMSCs in Patients With Alzheimer's Disease
Transplantation of Umbilical Cord-derived Mesenchymal Stem Cells Via Different Routes
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 23